Scientech Research LLC Has $1.42 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Scientech Research LLC lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 68.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,733 shares of the medical research company’s stock after buying an additional 1,115 shares during the quarter. Scientech Research LLC’s holdings in Thermo Fisher Scientific were worth $1,422,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Barrett & Company Inc. bought a new position in Thermo Fisher Scientific during the fourth quarter worth $28,000. FPC Investment Advisory Inc. bought a new position in Thermo Fisher Scientific during the fourth quarter worth $28,000. Missouri Trust & Investment Co bought a new position in Thermo Fisher Scientific during the fourth quarter worth $29,000. Pillar Financial Advisors LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $29,000. Finally, Endeavor Private Wealth Inc. bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $30,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares of the company’s stock, valued at approximately $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares of the company’s stock, valued at $59,506,950.58. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 14,075 shares of company stock worth $7,305,942 over the last ninety days. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 1.8%

Thermo Fisher Scientific stock opened at $412.15 on Friday. The company’s 50 day simple moving average is $453.88 and its 200 day simple moving average is $510.42. Thermo Fisher Scientific Inc. has a fifty-two week low of $390.50 and a fifty-two week high of $627.88. The firm has a market capitalization of $155.58 billion, a price-to-earnings ratio of 24.93, a PEG ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business’s quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the company posted $5.11 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a $0.43 dividend. The ex-dividend date of this dividend was Friday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.09%.

Analysts Set New Price Targets

TMO has been the topic of several analyst reports. Barclays lowered their target price on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Wednesday, April 23rd. Raymond James reiterated an “outperform” rating and set a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Finally, Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, April 24th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $607.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.